Associations among prognostic understanding, quality of life, and mood in patients with advanced cancer

Cancer

Volumn 120, Issue 2, 2014, Pages 278-285

  El Jawahri, Areej ^a   Traeger, Lara ^a   Park, Elyse R ^a   Greer, Joseph A ^b   Pirl, William F ^a   Lennes, Inga T ^a   Jackson, Vicki A ^b   Gallagher, Emily R ^a   Temel, Jennifer S ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

advanced cancer; illness understanding; mood; prognostic understanding; quality of life; supportive care

Indexed keywords

ADVANCED CANCER; AGED; ANXIETY; ARTICLE; ATTITUDE TO ILLNESS; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER PROGNOSIS; CLINICAL ARTICLE; CROSS-SECTIONAL STUDY; DIGESTIVE SYSTEM CANCER; FEMALE; FUNCTIONAL ASSESSMENT; FUNCTIONAL ASSESSMENT OF CANCER THERAPY GENERAL; HOSPITAL ANXIETY AND DEPRESSION SCALE; HUMAN; MALE; MEDICAL DECISION MAKING; MOOD; OBSERVATIONAL STUDY; PATIENT ATTITUDE; PATIENT EDUCATION; PRIORITY JOURNAL; PSYCHOSOCIAL CARE; QUALITY OF LIFE; QUESTIONNAIRE; TERMINAL CARE;

EID: 84891839587     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.28369     Document Type: Article

References (34)

1. Jonsen AR, Siegler M, Winslade W,. Clinical Ethics. 5th ed. New York: McGraw-Hill; 2002.
2. Faden R, Beauchamp TL,. A History and Theory of Informed Consent. New York: Oxford University Press; 1986.
3. Veatch RM,. Abandoning informed consent. Hastings Cent Rep. 1995; 25: 5-12.
4. Bayraktar S, Bayraktar UD, Rocha-Lima CM,. Recent developments in palliative chemotherapy for locally advanced and metastatic pancreas cancer. World J Gastroenterol. 2010; 16: 673-682.
5. Van Cutsem E, Van de Velde C, Roth A, et al. Expert opinion on management of gastric and gastro-oesophageal junction adenocarcinoma on behalf of the European Organisation for Research and Treatment of Cancer (EORTC)- gastrointestinal cancer group. Eur J Cancer. 2008; 44: 182-194.
6. Patt YZ, Hassan MM, Lozano RD, et al. Phase II trial of cisplatin, interferon alpha-2b, doxorubicin, and 5-fluorouracil for biliary tract cancer. Clin Cancer Res. 2001; 7: 3375-3380.
7. Patt YZ, Hassan MM, Aguayo A, et al. Oral capecitabine for the treatment of hepatocellular carcinoma, cholangiocarcinoma, and gallbladder carcinoma. Cancer. 2004; 101: 578-586.
8. Tsavaris N, Kosmas C, Gouveris P, et al. Weekly gemcitabine for the treatment of biliary tract and gallbladder cancer. Invest New Drugs. 2004; 22: 193-198.
9. Gallardo J, Rubio B, Villanueva L, Barajas O,. Gallbladder cancer, a different disease that needs individual trials. J Clin Oncol 23: 7753-7754, 2005; author reply 7754-7755.
10. Wagner AD, Grothe W, Haerting J, Kleber G, Grothey A, Fleig WE,. Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol. 2006; 24: 2903-2909.
11. Homs MY, v d Gaast A, Siersema PD, Steyerberg EW, Kuipers EJ,. Chemotherapy for metastatic carcinoma of the esophagus and gastro-esophageal junction [serial online]. Cochrane Database Syst Rev. 2006;(4): CD004063.
12. Meyerhardt JA, Li L, Sanoff HK, Carpenter W 4th, Schrag D,. Effectiveness of bevacizumab with first-line combination chemotherapy for Medicare patients with stage IV colorectal cancer. J Clin Oncol. 2012; 30: 608-615.
13. Brundage MD, Davidson JR, Mackillop WJ,. Trading treatment toxicity for survival in locally advanced non-small cell lung cancer. J Clin Oncol. 1997; 15: 330-340.
14. Hirose T, Yamaoka T, Ohnishi T, et al. Patient willingness to undergo chemotherapy and thoracic radiotherapy for locally advanced non-small cell lung cancer. Psychooncology. 2009; 18: 483-489.
15. Silvestri G, Pritchard R, Welch HG,. Preferences for chemotherapy in patients with advanced non-small cell lung cancer: descriptive study based on scripted interviews. BMJ. 1998; 317: 771-775.
16. Weeks JC, Cook EF, O'Day SJ, et al. Relationship between cancer patients' predictions of prognosis and their treatment preferences. JAMA. 1998; 279: 1709-1714.
17. Mack JW, Weeks JC, Wright AA, Block SD, Prigerson HG,. End-of-life discussions, goal attainment, and distress at the end of life: predictors and outcomes of receipt of care consistent with preferences. J Clin Oncol. 2010; 28: 1203-1208.
18. Temel JS, Greer JA, Admane S, et al. Longitudinal perceptions of prognosis and goals of therapy in patients with metastatic non-small-cell lung cancer: results of a randomized study of early palliative care. J Clin Oncol. 2011; 29: 2319-2326.
19. Zhang B, Wright AA, Huskamp HA, et al. Health care costs in the last week of life: associations with end-of-life conversations. Arch Intern Med. 2009; 169: 480-488.
20. Steinhauser KE, Christakis NA, Clipp EC, et al. Preparing for the end of life: preferences of patients, families, physicians, and other care providers. J Pain Symptom Manage. 2001; 22: 727-737.
21. Steinhauser KE, Christakis NA, Clipp EC, McNeilly M, McIntyre L, Tulsky JA,. Factors considered important at the end of life by patients, family, physicians, and other care providers. JAMA. 2000; 284: 2476-2482.
22. Weeks JC, Catalano PJ, Cronin A, et al. Patients' expectations about effects of chemotherapy for advanced cancer. N Engl J Med. 2012; 367: 1616-1625.
23. Gattellari M, Voigt KJ, Butow PN, Tattersall MH,. When the treatment goal is not cure: are cancer patients equipped to make informed decisions? J Clin Oncol. 2002; 20: 503-513.
24. Hagerty RG, Butow PN, Ellis PA, et al. Cancer patient preferences for communication of prognosis in the metastatic setting. J Clin Oncol. 2004; 22: 1721-1730.
25. Hancock K, Clayton JM, Parker SM, et al. Discrepant perceptions about end-of-life communication: a systematic review. J Pain Symptom Manage. 2007; 34: 190-200.
26. Wright AA, Zhang B, Ray A, et al. Associations between end-of-life discussions, patient mental health, medical care near death, and caregiver bereavement adjustment. JAMA. 2008; 300: 1665-1673.
27. Mack JW, Wolfe J, Grier HE, Cleary PD, Weeks JC,. Communication about prognosis between parents and physicians of children with cancer: parent preferences and the impact of prognostic information. J Clin Oncol. 2006; 24: 5265-5270.
28. Phelps AC, Maciejewski PK, Nilsson M, et al. Religious coping and use of intensive life-prolonging care near death in patients with advanced cancer. JAMA. 2009; 301: 1140-1147.
29. Prigerson HG,. Socialization to dying: social determinants of death acknowledgement and treatment among terminally ill geriatric patients. J Health Soc Behav. 1992; 33: 378-395.
30. Ray A, Block SD, Friedlander RJ, Zhang B, Maciejewski PK, Prigerson HG,. Peaceful awareness in patients with advanced cancer. J Palliat Med. 2006; 9: 1359-1368.
31. Chen JY, Tao ML, Tisnado D, et al. Impact of physician-patient discussions on patient satisfaction. Med Care. 2008; 46: 1157-1162.
32. Zigmond AS, Snaith RP,. The Hospital Anxiety and Depression Scale. Acta Psychiatr Scand. 1983; 67: 361-370.
33. Cella DF, Tulsky DS, Gray G, et al. The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J Clin Oncol. 1993; 11: 570-579.
34. Temel JS, Greer JA, Muzikansky A, et al. Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med. 2010; 363: 733-742.